Novo Nordisk narrative, tested by pricing pressure but supported by GLP-1 leadership For investors who see Novo Nordisk as a long-standing GLP-1 leader investing heavily in obesity and diabetes treatments, this episode fits into a broader pattern of defending its intellectual property while scaling new products like the Wegovy pill and CagriSema
No affiliation: PlexusDx is independent of LifeMD and holds no commercial relationship with any company discussed in this review
7 , e14139 (2019)
Thanks to its high nutritional value, it also contributes to the micronutrient intake of active people or those concerned about their diet
Peptide protocols involving GH-axis support may involve different concerns, such as fluid retention, joint discomfort, glucose changes, or contraindications depending on the patient
Murphy L, Shaker J, Buggy DJ